Researchers at the University of Southampton have discovered that lung cancer cells can change their identity to evade treatment by reverting to an earlier developmental state. This process, which is normally active during lung formation, allows cancer cells to become more aggressive and resistant to therapies such as chemotherapy and immunotherapy. The study, published in Molecular Oncology, analyzed data from over 1,500 patients and identified significant changes associated with disease progression and therapy resistance. Specifically, the loss of the TP53 gene, known for its cancer-protective properties, and the activation of interferon signaling pathways were found to drive this transition. Dr. Chris Hanley, the senior author, emphasized that understanding these mechanisms could lead to new treatment options for patients who currently do not respond well to existing therapies. The findings highlight the potential for personalized medicine in lung cancer treatment, enabling better predictions of patient responses to various therapies.